![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1471975
¼¼°èÀÇ ³×ºæ¶óÀÌÀú ½ÃÀå : ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ªº° Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® - À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Nebulizers Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, End User, and Geography |
¼¼°èÀÇ ³×ºæ¶óÀÌÀú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 8¾ï 1,588¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2023-2031³â¿¡ CAGR 6.2%·Î ¼ºÀåÇϸç, 2031³â¿¡´Â 13¾ï 1,557¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ÀçÅÃÄ¡·á¿ë È£Èí±â ±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª Á¶±â Áø´ÜÀÇ ºÎÁ·°ú ³×ºæ¶óÀÌÀú Ä¡·áÀÇ ³ôÀº ºñ¿ëÀº ³×ºæ¶óÀÌÀú ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
³×ºí¶óÀÌÀú ½ÃÀå µ¿Çâ
³×ºæ¶óÀÌÀú ±â¼úÀÇ º¯È´Â ÀÓ»óÀû ¿ä±¸¿Í Ư¼öÇÑ ±â¼ú ¹× ¼º´É Ư¼ºÀ» ÇÊ¿ä·Î ÇÏ´Â »õ·Î¿î ¾à¸®ÇÐÀû ¾à¹°ÀÇ °³¹ß·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. »õ·Î¿î ¾à¹°Àü´ÞÀ» ÃÖÀûÈÇϱâ À§ÇÑ °·ÂÇÑ °æÁ¦Àû ¾Ð·ÂÀ¸·Î ÀÎÇØ ³×ºæ¶óÀÌÀú Ä¡·á¿ë °æÁ¡¸· ¾à¹°Àü´Þ ½Ã½ºÅÛ°ú °°Àº Çõ½ÅÀûÀÎ Àü´Þ ÀåºñÀÇ °³¹ßÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î ÀÇÇÐÀû Áö½Ä°ú È¿°úÀûÀÎ ¾à¹°·Î ÀÎÇØ ´Ù¾çÇÑ À¯ÇüÀÇ ³×ºæ¶óÀÌÀú Ä¡·á°¡ °è¼Ó ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³×ºæ¶óÀÌÀú ±â¼úÀÇ ¹ßÀüÀº ¿¡¾î·ÎÁ¹À» »ý¼ºÇϱâ À§ÇØ ¸¶ÀÌÅ©·ÎÆßÇÁ ±â¼úÀ» »ç¿ëÇÏ´Â ¸Þ½¬ ³×ºæ¶óÀÌÀú¸¦ ź»ý½ÃÄ×½À´Ï´Ù. ³×ºæ¶óÀÌÀúÀÇ ¼ö¸¹Àº ÀåÁ¡°ú ÇÔ²² Á¦Ç° ½ÂÀÎ ¹× °³¹ß ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇâÈÄ ¼ö³â°£ ¼ö¿ä°¡ °È µÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ȸ»çÀÇ º¸µµ ÀÚ·á¿¡ µû¸£¸é ¸î °¡Áö ÁÖ¿ä °³¹ß ¹× ½ÂÀÎÀº ´ÙÀ½°ú °°½À´Ï´Ù.
2021³â 7¿ù, HCmed Innovations´Â Pulmogine Vibrating Mesh Nebulizer¿¡ ´ëÇÑ ¹Ì±¹ ½ÄǰÀǾ౹(FDA) ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. ÀÌ Àåºñ´Â HCmedÀÇ Ã·´Ü ±â¼úÀ» »ç¿ëÇÏ¿© ¾×ü ¾à¹°À» È£Èí±â¿¡ Á÷Á¢ Àü´ÞÇÒ ¼ö ÀÖ´Â ÀÛÀº ¿¡¾î·ÎÁ¹ ÀÔÀÚ·Î º¯È¯ÇÏ¿© È£Èí±â ÁúȯÀÇ ºÒÆíÇÔÀ» ¿ÏÈÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ Àåºñ´Â ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿ö ÈíÀÔ Ä¡·á°¡ ÇÊ¿äÇÑ È¯Àڵ鿡°Ô Æí¸®ÇÑ ¼Ö·ç¼ÇÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
2020³â 6¿ù, Respira Technologies, Inc.´Â RespiRx ¾à¹°Àü´Þ Àåºñ Ç÷§ÆûÀÎ RespiRx¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ »õ·Î¿î Ç÷§ÆûÀº õ½Ä ¹× COPD¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÀûÀÀÁõ¿¡ ´ëÇÑ ±¹¼Ò ¹× Àü½Å Ä¡·á¸¦ À§ÇÑ ÃʼÒÇü ÈÞ´ë¿ë ÇÚµåÇïµå Áøµ¿ ¸Þ½¬ ³×ºæ¶óÀÌÀú(VMN)´Ù. RespiRx´Â ÀÏȸ¿ë ÇÇ¿¡Á¶ ¼ÒÀÚ¿Í ¼ö¿ë¾×¿¡ ÇöŹµÈ ¾à¹°ÀÌ Æ÷ÇÔµÈ »çÀü ÃæÀüµÈ īƮ¸®Áö¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ÇüÅ´ ȯÀÚÀÇ ÆíÀǼºÀ» °í·ÁÇÏ¿© ¼³°èµÇ¾î ºÎÀûÀýÇÑ ¼¼Ã´À¸·Î ÀÎÇÑ ¿À·ù ¹× ¿À¿ëÀ» Á¦°ÅÇÕ´Ï´Ù. ÀÌ Ä«Æ®¸®Áö´Â Á¤È®ÇÑ Åõ¾àÀ» À§ÇØ ÇÁ·Î±×·¡¹ÖÀÌ °¡´ÉÇϸç, Åõ¾à·® ÃßÀû, µ¥ÀÌÅÍ ÃøÁ¤, ÀÇ·áÁøÀÇ ÀüÀÚ ÀÇ·á ±â·Ï ¼öÁýÀ» À§ÇÑ ºí·çÅõ½º ±â¼úÀÌ Å¾ÀçµÇ¾î ÀÖ½À´Ï´Ù.
µû¶ó¼ ´Ù¾çÇÑ ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÀÌ·¯ÇÑ ±â¼ú ¹ßÀü°ú Á¦Ç° ½ÂÀÎÀº ÇâÈÄ ¼ö³â°£ »õ·Î¿î ³×ºæ¶óÀÌÀú ½ÃÀå µ¿ÇâÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³×ºí¶óÀÌÀú ½ÃÀå ºÎ¹®º° °³¿ä
³×ºæ¶óÀÌÀú ½ÃÀåÀº À¯Çü, ¾ÖÇø®ÄÉÀÌ¼Ç ¹× ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó ¼¼ºÐȵ˴ϴÙ.
À¯Çüº°·Î´Â Á¦Æ® ³×ºæ¶óÀÌÀú, ÃÊÀ½ÆÄ ³×ºæ¶óÀÌÀú, ¸Þ½¬ ³×ºæ¶óÀÌÀú·Î ±¸ºÐµË´Ï´Ù. Á¦Æ® ³×ºæ¶óÀÌÀú ºÎ¹®Àº 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¸Þ½¬ ³×ºæ¶óÀÌÀú ºÎ¹®Àº 2023-2031³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦Æ® ³×ºæ¶óÀÌÀú´Â ¿¡¾î·ÎÁ¹ ÇüÅ·Π¾à¹°À» °ø±ÞÇÏ´Â Àú·ÅÇÏ°í »ç¿ëÇϱ⠽¬¿î Àåºñ·Î, ÀÏȸ¿ëÀ¸·Î ¼³°èµÇ¾î ¸ê±ÕÀÌ ÇÊ¿äÇÏÁö ¾Ê¾Æ ¿À¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. Á¦Æ® ³×ºæ¶óÀÌÀú´Â ÀϹÝÀûÀ¸·Î Àΰø È£Èí Áß¿¡ »ç¿ëµÇ¸ç, CRD Ä¡·á¿¡¼ ÀÌ·¯ÇÑ ³×ºæ¶óÀÌÀúÀÇ ´Ù¾çÇÑ ¿ëµµ´Â ¿¹Ãø ±â°£ Áß Á¦Æ® ³×ºæ¶óÀÌÀú ½ÃÀå ±Ô¸ð¸¦ Áõ°¡½ÃÄ×½À´Ï´Ù.
¿ëµµº°·Î ½ÃÀåÀº COPD, õ½Ä, ³¶Æ÷¼º ¼¶À¯Áõ, ±âŸ·Î ºÐ·ùµÇ¸ç, COPD ºÎ¹®Àº 2023³â °¡Àå Å« ³×ºæ¶óÀÌÀú ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. õ½Ä ºÎ¹®Àº 2023-2031³â °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COPD ȯÀÚ´Â ½ÉÀ庴, Æó¾Ï ¹× ±âŸ ´Ù¾çÇÑ Áúº´¿¡ °É¸± À§ÇèÀÌ ³ô½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é COPD´Â ¼¼°è 3À§ÀÇ »ç¸Á ¿øÀÎÀÔ´Ï´Ù. È£Èí±â ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÈíÀÔ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀçÅà ġ·á¿¡ ´ëÇÑ ¼±È£µµ º¯È·Î ÀÎÇØ COPD ¹× õ½Ä °ü¸®¿¡ ÈÞ´ë¿ë ³×ºæ¶óÀÌÀúÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é ³×ºæ¶óÀÌÀú ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ÀÀ±Þ¼¾ÅÍ, ÀçÅÃÀÇ·á·Î ±¸ºÐµË´Ï´Ù. º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®Àº 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ´Ù¾çÇÑ À¯ÇüÀÇ ³×ºæ¶óÀÌÀú¸¦ ÀÇ·á ÇöÀå¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ°í º´¿ø ȯ°æ¿¡¼ ÀÌ·¯ÇÑ ÀåºñÀÇ Ã¤Å÷üÀÌ ³ô¾ÆÁü¿¡ µû¶ó 2023-2030³â °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Áö¿ªº° ³×ºæ¶óÀÌÀú ½ÃÀå °³¿ä
³×ºæ¶óÀÌÀú ¼¼°è ½ÃÀå Á¶»ç ¹üÀ§´Â ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ¿µ±¹, ½ºÆäÀÎ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Àεµ, È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(³²¾ÆÇÁ¸®Ä«, »ç¿ìµð¾Æ¶óºñ¾Æ, ¾Æ¶ø ¿¡¹Ì¸®Æ®, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), Áß³²¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì)ÀÔ´Ï´Ù. 2023³â ³×ºæ¶óÀÌÀú ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì°¡ °¡Àå Å©°í À¯·´ÀÌ ±× µÚ¸¦ À̾î 2023³â ³×ºæ¶óÀÌÀú ½ÃÀå Á¡À¯À²Àº ºÏ¹Ì°¡ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó °³¹ß, ÀÇ·áºñ Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥, ÀÌ Áö¿ªÀÇ ´õ ³ªÀº ȯÀÚ °á°ú¿¡ ´ëÇÑ Á߿伺 Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
The nebulizers market was valued at US$ 815.88 million in 2023 and is expected to reach US$ 1315.57 million by 2031; it is estimated to record a CAGR of 6.2% during 2023-2031.
Key factors driving the market growth are the rising prevalence of chronic respiratory diseases and increasing demand for respiratory devices for home care settings are driving the growth of the market. However, the lack of early diagnosis and the high cost of nebulizing therapy hinder the nebulizers market growth.
Market Trends of the Nebulizers Market
Changes in nebulizer technology are driven by clinical needs and the development of new pharmacological agents, which require special techniques and performance characteristics. Due to strong economic pressures to optimize the delivery of newer medications, the development of innovative delivery devices, such as transmucosal drug delivery systems for nebulization therapies, has upscaled. With new medical knowledge and effective medicines, treatment with a wide range of nebulizers continues to advance. These advancements in nebulizer technology have led to the creation of mesh nebulizers that use micropump technology to produce aerosols. In addition to the numerous advantages of nebulizers, the growing number of product approvals and developments will likely strengthen the demand in the coming years. As per company press releases, a few major developments and approvals are listed below:
In July 2021, HCmed Innovations received US Food and Drug Administration (FDA) approval for Pulmogine Vibrating Mesh Nebulizer. It uses HCmed's advanced technology to convert liquid medication into tiny aerosol particles that can be directly delivered to the airways, relieving respiratory disease discomfort. Additionally, the device is portable and easy to use, making it a convenient solution for patients who require inhalation treatment.
In June 2020, Respira Technologies, Inc. launched its RespiRx drug delivery device platform. This novel platform is an ultra-portable handheld vibrating mesh nebulizer (VMN) for local and systemic treatment for various indications, including asthma and COPD. RespiRx offers a pre-filled cartridge that contains a disposable piezo element and the drug compound suspended in an aqueous solution. This format is designed for patients' convenience, eliminating errors and misuse due to improper cleaning. The cartridge is programmable to deliver precise doses and comes equipped with Bluetooth technology to track dose delivery, measure data, and collect electronic medical records for healthcare providers.
Therefore, such technological advancements by various market players and product approvals are anticipated to bring new nebulizers market trends in the coming years.
Nebulizers Market: Segmental Overview
The nebulizers market is segmented on the basis of type, application, and end- user.
By type, the market is segmented into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The jet nebulizers segment held the largest market share in 2022. The Mesh Nebulizers segment is projected to register the highest CAGR from 2023 to 2031. Jet nebulizers are affordable and easy-to-use devices that deliver medication in the form of aerosol. They are designed for one-time use, eliminating the need for sterilization and reducing contamination risk. Jet nebulizers are commonly used during mechanical ventilation. The various application of these nebulizers in treatment of CRD is propelling the jet nebulizers market size during the forecast period.
The market, by application, is segmented into COPD, asthma, cystic fibrosis, and others. The COPD segment is anticipated to hold the largest nebulizers market share in 2023. The asthma segment is projected to grow with the highest CAGR from 2023 to 2031. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. According to the World Health Organization (WHO), COPD is the third leading cause of death globally. The demand for inhalation therapies is also increasing with the increase in the burden of respiratory diseases. Additionally, the shift in preference for home care treatments fuels the utilization of handheld nebulizers for the management of COPD and asthma.
Based on end- user, the nebulizers market is segmented into hospitals and clinics, emergency centers, and home care settings. The hospitals and clinics segment held the largest share of the market in 2023 and is expected to register the highest CAGR from 2023 to 2030 owing to the medical availability of various types of nebulizers and the growing adoption rate of these devices in hospital settings.
Nebulizers Market: Geographical Overview
The scope of the global nebulizers market report entails North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held a major nebulizers market share in 2023, followed by Europe; the market in Asia Pacific region is growing with the highest CAGR during the forecast period. This is attributed to developing healthcare infrastructure in emerging markets, rising healthcare expenditure, lucrative reimbursement policies, and increasing emphasis on better patient outcomes in the region.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies